Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Phone calls go to voicemail, the in-portal chat icon doesnt function, and email replies take at least a business day
When combined with semaglutide, which also lowers blood glucose, there is theoretical potential for additive glucose-lowering effects, particularly in patients with diabetes who should monitor blood glucose levels more frequently
The American Physiological Society (1999)
The predominant side effects include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal pain (affecting 10-50% of patients depending on the specific product and dose, particularly during dose escalation) Injection site reactions : redness, itching, or discomfort at the subcutaneous injection site Hypoglycaemia : particularly when combined with insulin or sulphonylureas Decreased appetite : an intended therapeutic effect that contributes to weight loss However, some patients do report changes in urinary frequency or patterns
